Immuno-Oncology Evaluation Support
Go beyond tumor shrinkage by combining tumor microenvironment, immune-cell infiltration, checkpoint pathways, cytokines, and gene or protein expression to interpret anti-tumor activity and immune response.
KGAH-ONE works backward from the development question to organize the model, comparator, monotherapy or combination strategy, intervention timing, and tumor and immune readouts, then connects the program with suitable specialized partners.
Evaluate why a therapy works—or does not work—beyond tumor size alone.
Tumor volume or survival alone may not explain immune response, tumor microenvironment, target expression, immune-cell infiltration, or the biological basis of a combination effect.
KGAH-ONE organizes the mechanism and development hypothesis, then combines anti-tumor response, pathology, immune readouts, PD-L1, cytokines, and PK / PD biomarkers into one evidence package.
Which model and readouts can explain both anti-tumor activity and immune response?
Define whether the central question is direct tumor inhibition, immune-mediated activity, checkpoint modulation, or combination rationale.
Combine tumor response, pathology, immune cells, PD-L1, cytokines, and PK / PD to support the next development decision.
Interpret not only whether the program worked, but why, how candidates or doses differ, and whether monotherapy or combination is justified.
Four perspectives in immuno-oncology evaluation
Design tumor response and immune biology as one connected development hypothesis.
Anti-Tumor Activity
Evaluate tumor volume, tumor weight, tumor number / burden, survival, and dose response.
Pathology and Pharmacodynamic Action
Consider H&E, IHC, proliferation / apoptosis markers, and PK / PD biomarkers.
Immune Cells and Microenvironment
Combine CD8, macrophage, immune-cell infiltration, PD-L1, and cytokine readouts.
Monotherapy and Combination Strategy
Organize the rationale for checkpoint inhibitors, complementary mechanisms, sequencing, and timing.
Model options according to the development question
Start with tumor biology, immune context, mechanism, primary endpoint, and the next decision—not with a model name alone.
Human tumor-cell growth and drug response
Supports evaluation of direct anti-tumor activity, dose response, combination effect, and pharmacodynamic action.
- Tumor volume / weight
- Survival
- IHC and proliferation / apoptosis markers
- PK / PD biomarkers
HCC and tumor immune environment in a MASH background
Evaluates spontaneous HCC in a MASH background, including an ICI-low-response tumor immune environment.
- Tumor number / burden and survival
- H&E and IHC
- CD8 / macrophage infiltration
- PD-L1 and cytokines
- ICI and combination therapy
Syngeneic / Humanized Mouse Options
Where an immune-system-containing evaluation is required, these may be considered according to the development question. Feasibility, model, tumor type, immune context, and responsible partner should be confirmed individually.
- Immune-mediated response
- Checkpoint pathway
- Immune-cell profiling
- Combination strategy
The “30+ studies” statement applies specifically to STAM™-IO. Syngeneic and humanized mouse options are presented as approaches that can be considered, not as an SMC Laboratories track-record claim.
Evidence package connecting anti-tumor activity and immune response
Avoid relying on a single readout. Design a combination that can explain effect, reason, and the next development action.
Tumor Burden
Tumor volume, weight, number, burden, and survival as primary anti-tumor response measures.
Histopathology
H&E, IHC, proliferation, and apoptosis markers at the tissue and cellular level.
Immune Infiltration
CD8, macrophage, and other immune-cell infiltration within the tumor microenvironment.
Checkpoint / Cytokine
PD-L1, cytokines, and other readouts related to immune state and checkpoint pathways.
PK / PD and Decision
Exposure, target action, candidate differences, dose, monotherapy or combination, and Go / No-Go.
Connect the evaluation system with the next development decision
The objective is not study execution itself, but clarity on which candidate and condition should move forward.
Development Hypothesis
Define whether the main hypothesis is direct tumor activity, immune-mediated action, checkpoint modulation, or combination effect.
Model and Comparator
Organize the model, groups, dose, intervention timing, positive control, monotherapy, and combination conditions.
Tumor and Immune Readouts
Combine tumor response, pathology, immune infiltration, PD-L1, cytokines, and PK / PD.
Next Development Decision
Connect the results with candidate ranking, dose, combination rationale, additional validation, Go / No-Go, or next dog and cat studies.
The same degree of tumor shrinkage may have a different development meaning.
The next candidate, dose, combination partner, and endpoint will differ depending on whether the effect is driven by direct cytotoxicity, immune activation, microenvironmental change, target action, or combination synergy.
Representative public track record of a specialized partner
These are externally usable performance statements from SMC Laboratories. KGAH-ONE leads problem definition and coordination design.
Connect anti-tumor activity and immune response with the next development decision.
Tell us the tumor type, modality, mechanism of action, candidate stage, expected monotherapy or combination strategy, and current development question. KGAH-ONE can help organize the model, tumor and immune endpoints, pathology, biomarkers, and specialized partner pathway.
KGAH-ONE is an Animal Health intelligence and partner coordination platform of Kawasaki Global Animal Health, Inc. Specialized oncology, immuno-oncology, pathology and nonclinical evaluation support may be provided by partners such as SMC Laboratories, depending on the development question.